Category: Opioid Epidemic

  • Medical Schools Rethink Training Amid Opioid Epidemic

    Medical Schools Rethink Training Amid Opioid Epidemic

    Some medical schools around the country have begun to change the conversation around pain management.

    Medical schools are rethinking how they train doctors in pain management and addiction treatment, in hopes of graduating a generation of medical professionals that are better able to serve the needs of patients living amid the opioid epidemic. 

    In a recent role-play exercise at the Warren Alpert Medical School of Brown University, students talked to a patient about her back pain, and learned to ask an important question: “Have you ever taken any medications that weren’t prescribed to you?” 

    “To be perfectly honest I stopped buying the Percs because they were too expensive, and I started buying heroin, because it was cheaper. I’ve been doing the heroin for the past 5 months,” the woman playing the patient replied. 

    Dr. Paul George, associate dean of medical education at Brown, told WBUR that the exercise is a realistic representation of what pain doctors may face. “The point of that workshop is for the students to work together to show it really does take a team to care for folks who are using substances inappropriately,” he said. 

    Recently, Brown and the University of Massachusetts (UMass) were both recognized by the Association of American Medical Colleges for their proactive approaches to teaching medical students about pain management and addiction. 

    At UMass, Jill Terrien teaches graduate-level nursing students to talk to their patients about pain. Rather than treating pain as the fifth vital sign and aiming to mitigate it, Terrien encourages nurses to tell patients that they should expect some pain after undergoing major procedures like surgery. 

    “In our curriculum now, we’re more deliberate about [telling patients] ‘you’re going to have pain,’” she said. “That way patients don’t expect that a) they’re going to get opioids because that’s what they’ve always gotten, and b) that might not be the best treatment for them.”

    In addition to changing the conversation around pain management, UMass and Brown both provide all medical students the training they will need to prescribe buprenorphine, a medication commonly used for medication-assisted treatment.

    Currently, under 7% of doctors hold the waiver needed to prescribe buprenorphine, and the medical schools feel that needs to change. 

    “They can prescribe Oxycontin, they can prescribe morphine. It seems almost unfair they can’t prescribe a medication that is used to treat some of the consequences of prescribing opioids,” said Sarita Warrier, associate dean of medical education at Brown.

    Paul Wallace, who recently graduated from medical school at Brown, agreed. 

    He said, “It helps dispel the notion that treating opioid use disorder is purely the domain of addiction specialists or primary care doctors, when truly all different types of physicians are going to encounter patients with opioid use disorder, whether it’s an emergency physician seeing a patient after an overdose or an obstetrician working with a patient with opioid use disorder.”

    View the original article at thefix.com

  • Minnesota Makes Move To Get Drug Companies To Indirectly Pay For Addiction Treatment

    Minnesota Makes Move To Get Drug Companies To Indirectly Pay For Addiction Treatment

    The new plan is anticipated to help put about $20 million annually toward the prevention of substance use disorders, as well as treatment for them.

    Minnesota is increasing fees for drug companies in an effort to pay for the effects of the opioid epidemic in the state. 

    On May 29, Minnesota Governor Tim Walz signed into law a bill that will drive up fees for both prescription drug manufacturers and distributors, the Star Tribune reports.  

    The new plan is anticipated to help raise about $20 million annually toward the prevention of substance use disorders, as well as treatment for them.

    For drug manufacturers and distributors, the new plan isn’t a minor change. It will drive their annual licensing fees from about $200 annually to $305,000 annually. After five years, the Star Tribune reports, those fees will decrease to $5,000 if state funding hits the goal of $250 million. This could be through the increased fees for companies, or via a settlement from existing lawsuits against such organizations. 

    “The opioid epidemic is devastating communities across Minnesota—claiming lives and leaving heartbroken families in its wake,” Walz said in a statement. “This law will help more families access the treatment they need and prevent addiction in the first place.”

    The Star Tribune reports that an advisory council made up of 19 members will monitor the funding and be responsible for issuing grants for programs that aim to combat the opioid crisis and prevent additional deaths as a result. The funding will also be allocated to various law enforcement areas, programs that work to provide nonnarcotic pain treatment and county services for children who have been affected by the opioid epidemic. 

    “This is unusual,” said Carmen Catizone, executive director of the National Association of Boards of Pharmacy, according to Kaiser Health News. “We keep seeing the states trying to find new ways to finance the costs of the opioid crisis. But this is a new angle, although it follows a pattern of states and municipalities assessing costs for disposing of unwanted or unused medicines.”

    However, the new legislation wasn’t supported by everyone. There was some pushback from chronic pain patients, as well as pharmaceutical companies themselves. 

    “Unfortunately, what’s being proposed—taxing legitimately prescribed medicines that patients rely on for legitimate medical needs to raise revenue for the state—ignores evidence-based solutions, sets a dangerous precedent and ultimately won’t help patients and families,” Nick McGee, director of public affairs for the industry trade group PhRMA, said earlier this year.

    According to the Star Tribune, such opposition in past years kept similar ideas from being enacted. However, increasing awareness around the opioid epidemic and the role of manufacturers and distributors helped to sway the dynamic. 

    View the original article at thefix.com